1 / 10

GLP-1 Effectiveness, Mechanisms of Action and Potential

GLP-1 Effectiveness, Mechanisms of Action and Potential. Part 3. *. *. *. *. *. *. *. *. *. *. *. *. Effect of GLP-1 on Fasting Hyperglycemia in Patients With T2DM. Glucose (mg/dL). C-Peptide (nmol/L). Glucagon (pmol/L). GLP-1. GLP-1. GLP-1. GLP-1 Saline. * P <0.05.

michaelathompson
Download Presentation

GLP-1 Effectiveness, Mechanisms of Action and Potential

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GLP-1 Effectiveness, Mechanisms of Action and Potential Part 3

  2. * * * * * * * * * * * * Effect of GLP-1 on Fasting Hyperglycemia in Patients With T2DM Glucose (mg/dL) C-Peptide (nmol/L) Glucagon (pmol/L) GLP-1 GLP-1 GLP-1 GLP-1 Saline *P<0.05 Adapted from Nauck MA, et al.Diabetologia. 1993;36:741-744.

  3. GLP-1 or Placebo GLP-1 or Placebo Placebo Placebo P < .001 * GLP-1 * * * * * * * GLP-1 * P < .001 * * * * * * GLP-1 Decreases Glucagon and Glucose Levels in Patients with Type 1 Diabetes Creutzfeldt WO, et al. Diabetes Care. 1996;19:580-6.

  4. Role of glucagon in impaired glucose tolerance Mitrakou et al. N Engl J Med 326:22, 1992

  5. The effect of impaired glucagon suppression on plasma glycemia is dependent on insulin Glucagon Glucagon Insulin Non-diabetic Diabetic HGP Glucose Glucose HGP Non-diabetic Diabetic AJP 277:E283;1999

  6. Placebo Exenatide 0.10 μg/kg sc 0 60 120 180 Time (min) Exenatide or placebo Exenatide Reduces Postprandial Glucagon Secretion in Patients With Type 2 Diabetes Meal 200 150 Plasma Glucagon (ng/L) 100 50 0 N = 20.Mean (SE). Glucagon AUC was significantly lower on day 5 with exenatide compared with placebo, P = .0123. Adapted from Kolterman OG, et al. J Clin Endocrinol Metab. 2003;88:3082-3089.

  7. Effect of one weeks treatment with a GLP-1R Agonist on glycemia and HGP Diabetes, 53:1187;2004

  8. Postprandial metabolism in T2DM with and without DPP-4 inhibition K Azuma, JCEM 2008

  9. Islet cell response to hypoglycemia with and without DPP-4 inhibition Δ Glucagon Vlda 47 ng/L Cntl 34 ng/L Δ ISR Vlda -70 pmol/m2/min Cntl -62 pmol/m2/min Δ PP Vlda 115 pmol/L Cntl 62 pmol/L B Ahren, JCEM 2009

  10. Treatment with Exenatide does not impair the counterregulatory glucagon response Diabetes 53:2397;2004

More Related